TOSYMRA Drug Patent Profile

Which patents cover Tosymra, and what generic alternatives are available?

Tosymra is a drug marketed by Tonix Meds and is included in one NDA. There are nine patents protecting this drug.

This drug has one hundred and six patent family members in thirty-four countries.

The generic ingredient in TOSYMRA is sumatriptan. There are twenty-four drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the sumatriptan profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tosymra

A generic version of TOSYMRA was approved as sumatriptan by LANNETT CO INC on February 19^th, 2016.

Summary for TOSYMRA

International Patents:	106
US Patents:	9
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	70
Patent Applications:	6,606
Drug Prices:	Drug price information for TOSYMRA
What excipients (inactive ingredients) are in TOSYMRA?	TOSYMRA excipients list
DailyMed Link:	TOSYMRA at DailyMed

See drug prices for TOSYMRA

Pharmacology for TOSYMRA

Drug Class	Serotonin-1b and Serotonin-1d Receptor Agonist
Mechanism of Action	Serotonin 1b Receptor Agonists Serotonin 1d Receptor Agonists

US Patents and Regulatory Information for TOSYMRA

TOSYMRA is protected by nine US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Tonix Meds	TOSYMRA	sumatriptan	SPRAY;NASAL	210884-001	Jan 25, 2019		RX	Yes	Yes	9,211,282		Y
Tonix Meds	TOSYMRA	sumatriptan	SPRAY;NASAL	210884-001	Jan 25, 2019		RX	Yes	Yes	9,283,280		Y
Tonix Meds	TOSYMRA	sumatriptan	SPRAY;NASAL	210884-001	Jan 25, 2019		RX	Yes	Yes	11,337,962		Y
Tonix Meds	TOSYMRA	sumatriptan	SPRAY;NASAL	210884-001	Jan 25, 2019		RX	Yes	Yes	12,090,139		Y

Expired US Patents for TOSYMRA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Tonix Meds	TOSYMRA	sumatriptan	SPRAY;NASAL	210884-001	Jan 25, 2019	8,268,791
Tonix Meds	TOSYMRA	sumatriptan	SPRAY;NASAL	210884-001	Jan 25, 2019	9,283,280
Tonix Meds	TOSYMRA	sumatriptan	SPRAY;NASAL	210884-001	Jan 25, 2019	8,440,631

EU/EMA Drug Approvals for TOSYMRA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Galpharm Healthcare Ltd.	Sumatriptan Galpharm	sumatriptan	EMEA/H/C/002140	Refused	yes	no	no		2012-02-09

International Patents for TOSYMRA

See the table below for patents covering TOSYMRA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2010299607	Formulations comprising triptan compounds
Canada	2775404	FORMULATIONS COMPRENANT DES COMPOSES TRIPTAN (FORMULATIONS COMPRISING TRIPTAN COMPOUNDS)
China	102933198	Formulations comprising triptan compounds
Denmark	2480197

Supplementary Protection Certificates for TOSYMRA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3678649	301317	Netherlands		PRODUCT NAME: COMBINATIE VAN EPINEFRINE OF EEN ZOUT DAARVAN, EN DODECYLMALTOSIDE; REGISTRATION NO/DATE: EU1/24/1846 20240823
3678649	CA 2025 00007	Denmark		PRODUCT NAME: KOMBINATION AF EPINEPHRIN ELLER ET SALT DERAF, OG DODECYLMATOSID; REG. NO/DATE: EU/1/24/1846 20240823
3678649	PA2025507	Lithuania		PRODUCT NAME: VISU FORMU EPINEFRINO IR DODECILMALTOZIDO DERINYS SAUGOMASPAGRINDINIO PATENTO; REGISTRATION NO/DATE: EU/1/24/1846 20240822
3678649	C20250011	Finland

Last updated: July 29, 2026

Tosymra (sumatriptan nasal spray) market dynamics and financial trajectory: exclusivity timeline, revenue drivers, and generic-risk outlook

Tosymra (sumatriptan) nasal spray, built on a competitively advantaged delivery route versus injectable and tablet sumatriptan, is operating in a mature migraine-treatment market with strong headwinds from (1) long-standing generic pressure in oral triptans, (2) limited payer tolerance for premium priced branded migraine agents, and (3) narrow volume capture outside higher-acuity, time-to-dose segments. The financial trajectory is dominated by reimbursement dynamics, channel access, and the durability of IP/exclusivity for the nasal delivery system.

---

What is Tosymra’s current market position and who competes with it in acute migraine?

Tosymra targets acute treatment of migraine with and without aura, using a rapid intranasal dosing profile designed to reduce delay versus oral administration. In the acute migraine stack, it competes against:

• Oral triptans (generic sumatriptan, rizatriptan, zolmitriptan, naratriptan, eletriptan, etc.)
• Other branded acute migraine therapies with specific route advantages (where formulary access exists)
• Rescue and non-triptan acute options depending on patient history and payer preferences

Market reality: acute migraine is price-sensitive and substitution-heavy. Once payers build access to lower-cost oral generics, route-specific products must win on speed, adherence, and patient-specific contraindications (e.g., inability to swallow during nausea/vomiting) to sustain premium pricing.

---

How do payer dynamics and formulary placement affect Tosymra revenue growth?

Revenue for route-specific branded migraine agents typically depends on:

1. Formulary tiering and prior authorization
   The more restrictive the pathway, the more the product leans on specialty pharmacies and narrow patient cohorts. Tosymra’s intranasal route increases the probability of payer policy scrutiny because cost-per-dose is higher than oral generic triptans.

2. Step therapy pressure
   Many plans require failure or inadequate response to oral triptans before allowing branded intranasal agents. That reduces addressable volume, particularly in lower-acuity migraine patients.

3. Channel mix: pharmacy vs specialty vs buy-and-bill (if any)
   For intranasal acute products, retail pharmacy fulfillment usually dominates; specialty distribution is less common unless payer policies trigger specialty pharmacy requirements.

4. Patient segment targeting
   Tosymra’s value proposition is strongest where rapid onset matters and where oral dosing is compromised. If prescribing patterns widen to broader migraine populations, the unit economics can compress quickly under payer pressure.

Bottom line: Tosymra’s financial trajectory is more sensitive to payer coverage than to head-to-head clinical superiority because the acute migraine market’s default economic strategy is to treat with the cheapest clinically acceptable option, often an oral generic.

---

What exclusivity timeline applies to Tosymra and when does it lose patent protection?

Tosymra’s exclusivity outcome is governed by two layers: (1) regulatory exclusivity and (2) patent estate coverage of the product, including drug substance, formulation, device/delivery system, and method-of-use claims.

Risk profile: intranasal dosage forms often face denser formulation and device-adjacent patent coverage than oral tablets, but the exclusivity landscape can still be eroded by paragraph IV challenges if the Orange Book listing includes product patents that are vulnerable on novelty/obviousness or obvious variants.

Required outcome for investors/licensing: Tosymra’s peak sales and durability hinge on whether product is still protected from generic intranasal sumatriptan products and whether alternatives can be substituted at the payer level before expiration.

No patent-expiration dates or Orange Book listing details are provided here because complete, accurate Tosymra patent and FDA listing data is not available in the information supplied.

---

How strong is the patent estate for Tosymra versus generic intranasal sumatriptan risks?

A nasal route can produce a more robust IP moat through:

• formulation patents (e.g., composition, pH/solubilization approach, excipients, spray characteristics)
• delivery or device patents (spray head design, dosing accuracy, plume characteristics)
• process/manufacturing method patents for sprayable/instilled suspensions or solutions

Generic risk mechanics:
For Tosymra, generic exposure typically depends on whether a challenger can (a) obtain approval for a pharmaceutically equivalent nasal spray and (b) design around formulation/device patents while maintaining bioequivalence.

Business interpretation: Even when chemical entity protection is gone for sumatriptan, the nasal delivery system can maintain exclusivity if formulation/device claims remain enforceable until later dates.

No detailed patent list, claim coverage mapping, or expiration schedule is provided because it is not available in the supplied information.

---

What generic entry risks exist for Tosymra (paragraph IV and settlement scenarios)?

Paragraph IV outcomes in branded nasal products are commonly driven by:

• whether the Orange Book lists patents are enforceable and relevant to approval (core product patents versus peripheral formulation/process patents)
• the litigation posture and expected duration of stays
• settlement structure (typical frameworks include market entry at a set date, license-backed launch terms, or non-overlapping distribution constraints)

Commercial consequence:
A paragraph IV filing can depress branded uptake even before generic launch because payers and providers prepare substitution plans, and wholesalers may adjust inventory and distribution behavior.

No information is available here about any Tosymra paragraph IV filings, litigation, or settlements.

---

What is the Orange Book status of Tosymra (listed patents and exclusivity categories)?

Orange Book status determines:

• the exact patents tied to regulatory approval
• which patents can support a paragraph IV challenge
• the remaining period of exclusivity or listed patent protection for each claim set

No Orange Book listing contents are provided in the information supplied, so no accurate list of Tosymra patents or exclusivity expirations can be stated.

---

How does Tosymra compare financially with oral generic sumatriptan and other acute migraine options?

Financial performance for route-shift products usually depends on premium pricing plus net-to-gross managed through rebates and access programs. Against oral generics:

• oral generics reset the pricing floor
• intranasal products must win on route utility and payor willingness to cover for “fail/contraindication” cohorts
• the most durable revenue tends to occur where intolerance to oral dosing is prevalent, or where payer policy explicitly covers the intranasal option after failure criteria

Competitive comparison logic used by payers:

• clinical differentiation (time-to-dose, tolerability with nausea)
• formulary preference (tier placement, prior authorization burden)
• administrative ease (switching policies, substitution rules)
• budget impact (cost-per-month for covered patient cohorts)

No revenue or unit sales figures for Tosymra, oral sumatriptan, or specific competitors are provided in the information supplied, so no quantified financial trajectory can be computed.

---

What FDA regulatory pathway history shaped Tosymra’s launch and subsequent pricing leverage?

Tosymra’s FDA regulatory pathway affects launch timing, exclusivity periods, and the probability of later generic competition. Route-specific intranasals often arrive as brand-new dosage forms even when the active ingredient is old, which can change:

• the type of exclusivity attached to the approval
• the structure of subsequent patent listings
• the willingness of payers to accept a premium at launch before the market matures

No FDA approval dates, exclusivity grants, or regulatory milestone dates for Tosymra are provided in the information supplied.

---

What commercial drivers determine Tosymra’s revenue trajectory: dosing frequency, retention, and prescriber behavior?

For acute migraine therapies, revenue is shaped by three demand levers:

1. Dosing frequency per treated patient
   Acute migraine dosing is episodic. Average monthly dose depends on attack frequency and persistence with the product.

2. Patient retention across migraine episodes
   If patients perceive adequate symptom relief and minimal adverse effects, they remain with the agent. Failure shifts patients to oral triptans or alternative therapies.

3. Prescriber behavior and early-cycle adoption
   Brand uptake during the first sales cycles can set expectations with payers and channel partners, impacting later access.

Route-specific adoption effect:
Intranasal adoption increases where speed and swallowing constraints matter. If prescribers use it broadly as “any acute migraine option,” reimbursement friction grows and net pricing typically erodes.

---

How do pricing, rebates, and net sales mechanics influence Tosymra profitability over time?

Branded migraine agents usually show:

• higher gross price than oral generics
• material rebate adjustments tied to formulary performance and volume commitments
• net sales sensitivity to payer contracting cycles

The key profitability hinge is whether Tosymra’s incremental patient coverage offsets discounting pressure. If payer access broadens faster than discounts, net revenue can expand. If payer access is narrow and rebating remains high, revenue can plateau.

No Tosymra pricing, rebate, net sales, or gross-to-net data is provided in the information supplied.

---

What manufacturing and supply-chain factors could affect Tosymra market performance?

Intranasal products face operational risk from:

• device/spray performance consistency and lot-to-lot reproducibility
• fill-finish capacity for nasal dosing hardware
• stability constraints for formulations and packaging

Supply disruptions tend to create:

• short-term lost sales and delayed reorders
• payer switching risk if coverage policies permit alternative products

No manufacturing site data, FDA inspection outcomes, or supply interruptions for Tosymra are provided in the information supplied.

---

Key Takeaways

• Tosymra is positioned in acute migraine where route utility can justify premium coverage, but revenue is structurally constrained by payer step therapy and substitution to oral triptans.
• The financial trajectory is most sensitive to formulary access durability, prior authorization burden, and the pace of generic substitution once IP and/or exclusivity ends.
• A credible generic entry assessment requires Tosymra’s Orange Book patent list, paragraph IV and litigation history, and exact expiration dates, none of which are present in the supplied information.

---

FAQs

1. How do prior authorization and step edits typically impact intranasal migraine brands like Tosymra?
2. What are the main reimbursement differentiators between intranasal sumatriptan and oral generic triptans?
3. How does the Orange Book patent listing format affect paragraph IV generic risk for dosage-form-specific products?
4. What settlement structures most commonly delay generic intranasal entry in branded migraine products?
5. What manufacturing constraints can materially affect sustained availability for nasal spray therapies?

---

References

1. (No citable sources were provided in the information supplied.)